Fetal Tuberous Sclerosis: Sirolimus for the Treatment of Fetal rhabdomyoma.
Fetal Pediatr Pathol
; 41(5): 800-806, 2022 Oct.
Article
en En
| MEDLINE
| ID: mdl-34281475
ABSTRACT
BACKGROUND:
Sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (TSC) in children but only four cases describing prenatal treatment of rhabdomyomas with mTOR inhibitors have been published. CASE In this case, sirolimus was initiated at 26 weeks´ gestation in a pregnant woman with TSC with a fetus with a large rabdomyoma conditioning severe arrythmia. There was a significant reduction in the tumor size with ongoing treatment and a partial reversion of the arrythmia.CONCLUSION:
m-TOR inhibitors can be considered for severe cases of fetal rhabdomyomas with poor prognosis given its potencial benefits.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Rabdomioma
/
Esclerosis Tuberosa
/
Neoplasias Cardíacas
Límite:
Child
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Fetal Pediatr Pathol
Asunto de la revista:
PATOLOGIA
/
PEDIATRIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Portugal